Nutriband Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended July 31, 2023; filed September 8, 2023. Figures are unaudited. The company develops transdermal pharmaceutical products, including its lead AVERSA abuse-deterrent fentanyl patch, and also earns revenue from coated-product manufacturing and contract services.
Key financial metrics
| Metric | Three months ended July 31, 2023 | Six months ended July 31, 2023 |
|---|---|---|
| Revenue | $655,928 | $1,132,860 |
| Gross profit / margin | $299,672 / 45.7% | $521,956 / 46.1% |
| Operating loss | $824,188 | $1,842,066 |
| Net loss | $829,173 | $1,844,402 |
| Net loss per share | $0.11 | $0.24 |
For the six-month period, operating cash flow was negative $1,744,999, investing cash flow was negative $2,624, and financing cash flow was positive $2,096,736. Cash increased by $349,113 to $2,334,553. At July 31, current assets were $3,273,573 and current liabilities were $874,127, giving working capital of $2,399,446. Total liabilities were $2,981,920. Notes payable and related-party debt totaled approximately $2.217 million, including a $2.0 million related-party advance; lease liabilities are additional.
Changes versus prior comparable periods
- Quarterly revenue rose 43.8% from $456,149; six-month revenue rose 21.3% from $934,071. Six-month product sales were $967,826 and service revenue was $165,034; all reported revenue was from the United States.
- Quarterly gross profit increased from $151,796 to $299,672; six-month gross profit increased from $352,282 to $521,956. Gross margin improved to 45.7% for the quarter and 46.1% for six months, versus 33.3% and 37.7%, respectively, in 2022.
- Six-month R&D expense increased to $845,552 from $395,683, primarily reflecting AVERSA development costs and Kindeva work. Six-month SG&A declined to $1,518,470 from $1,676,724.
- Six-month net loss widened to $1,844,402 from $1,728,664. Operating cash use increased from $1,652,750 to $1,744,999.
Outlook, risks and notable items
- No formal revenue or earnings guidance is provided. Management says it expects available resources to fund operations for at least one year from the financial statements’ issuance date and believes substantial going-concern doubt is alleviated. The company nonetheless reported continuing losses and operating cash use.
- The July 2023 amendment increased a three-year credit line from a related-party shareholder to $5 million, at 7% interest and due July 31, 2026. $2 million had been advanced by July 31, leaving potential additional capacity subject to the facility’s terms.
- Management estimates approximately $13 million will be required for AVERSA fentanyl development, including clinical manufacturing and trials; costs could be higher. The lead product remains in development and requires FDA approval, with no assurance of approval or commercialization.
- A $106,528 advance against a $118,675 bankruptcy claim was recorded as a secured borrowing; the company may have to repay amounts if the claim is reduced or unpaid. A separate dispute with Joseph A. Gunnar concerns fees; the company says any loss range cannot presently be estimated.
- Cash balances of approximately $1.47 million exceeded federally insured limits. Disclosure controls were deemed ineffective; management cited material weaknesses involving segregation of duties and accounting staffing, while describing remediation steps.
- Other risks include clinical and regulatory delays, further financing needs, manufacturing and distribution execution, and possible disruption from public-health events. The filing reports no material off-balance-sheet arrangements.
Important facts for investors to verify
- Progress, remaining cost and timing for the Kindeva workplan and AVERSA clinical development, including the basis for the estimated $13 million funding need.
- Availability and conditions of the related-party credit facility, including remaining borrowing capacity, covenants and future interest obligations.
- Cash runway assumptions supporting management’s one-year liquidity outlook, given reported operating cash burn and continuing losses.
- Status and potential financial exposure of the Sorrento bankruptcy claim and the Gunnar fee dispute.
- Remediation of the disclosed material weaknesses and whether disclosure controls become effective.